Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOM230 pilot trial in Graves orbitopathy
NL-OMON26944Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2013
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of pasireotide LAR in Graves' ophthalmopathy (TED), sponsored by Amsterdam University Medical Center. Primary endpoint: Overall ophthalmic/endocrine assessment at week 12. Planned start Apr 2013; status: not yet recruiting.
02
Drugs
pasireotide LAR
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on NL-OMON26944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26944.